These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 30105359)

  • 21. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

  • 22. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 23. The needs of the few.
    Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
    [No Abstract]   [Full Text] [Related]  

  • 24. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 25. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
    Goozner M
    J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
    [No Abstract]   [Full Text] [Related]  

  • 26. Regulatory perspectives on data monitoring.
    O'Neill RT
    Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2015 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2016 Feb; 15(2):73-6. PubMed ID: 26837582
    [No Abstract]   [Full Text] [Related]  

  • 28. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 29. "Fast tracking" drug approvals: is consumer safety being compromised?
    Jacobsen K
    QRC Advis; 2000 Jun; 16(8):5-9. PubMed ID: 10977137
    [No Abstract]   [Full Text] [Related]  

  • 30. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Electronic medical record in clinical trials of effectiveness of drugs integrated in clinical practice].
    Carcas AJ; Abad Santos F; Sánchez Perruca L; Dal-Ré R
    Med Clin (Barc); 2015 Nov; 145(10):452-7. PubMed ID: 25913907
    [No Abstract]   [Full Text] [Related]  

  • 32. More Than One Way to Measure? A Casuistic Approach to Cancer Clinical Trials.
    Andreoletti M
    Perspect Biol Med; 2018; 61(2):174-190. PubMed ID: 30146517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical studies in pediatrics: challenges and actual developments].
    Ohmann C
    Klin Padiatr; 2008; 220(4):221-3. PubMed ID: 18654944
    [No Abstract]   [Full Text] [Related]  

  • 35. Regulatory inspection of clinical trials in Nigeria.
    Keri HJ
    Nig Q J Hosp Med; 2008; 18(2):120-2. PubMed ID: 19068566
    [No Abstract]   [Full Text] [Related]  

  • 36. How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?
    Berger ML; Crown W
    Value Health; 2022 Feb; 25(2):167-170. PubMed ID: 35094788
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceutical and Medical Devices: FDA Oversight.
    White RS;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-97. PubMed ID: 27116797
    [No Abstract]   [Full Text] [Related]  

  • 38. Project Zero Delay: a process for accelerating the activation of cancer clinical trials.
    Kurzrock R; Pilat S; Bartolazzi M; Sanders D; Van Wart Hood J; Tucker SD; Webster K; Mallamaci MA; Strand S; Babcock E; Bast RC
    J Clin Oncol; 2009 Sep; 27(26):4433-40. PubMed ID: 19652061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Encouraging research and development of pediatric medical devices through legislative and regulatory action: the Pediatric Medical Device Safety and Improvement Act of 2007 in context.
    Bleicher EW
    Food Drug Law J; 2009; 64(3):531-64. PubMed ID: 19999642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. US Food and Drug Administration and design of drug approval studies.
    Woloshin S; Schwartz LM; Frankel B; Faerber A
    JAMA; 2014 Nov; 312(20):2163-5. PubMed ID: 25423223
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.